SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective
8 references·0 citing·43 second hopsampled
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective (2016)Cost-effectiveness of adding carfilzomib …Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)Updating Cost-Effectiveness —…Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma (2014)Mapping EORTC QLQ-C30 and QLQ…Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data (2013)Survival Analysis for Economi…Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study (2010)Population preference values …Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing (2009)Efficacy Does Not Necessarily…What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)What Does the Value of Modern…Adjusting the Value of a Statistical Life for Age and Cohort Effects (2008)Adjusting the Value of a Stat…Do Oncologists Believe New Cancer Drugs Offer Good Value? (2006)Do Oncologists Believe New Ca…Willingness to Pay for a Quality-adjusted Life Year (2000)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research (2016)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Economics and mental health: the current scenario (2020)Measurement of health state utilities for economic appraisal (1986)Modeling Valuations for EuroQol Health States (1997)EQ-SD: a measure of health status from the EuroQol Group (2001)Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia (2012)Use of Conjoint Analysis to Assess Breast Cancer Patient Preferences for Chemotherapy Side Effects (2014)Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (2021)Development of WHO guidelines on generalized cost-effectiveness analysis (2000)The Health Utilities Index (HUI): concepts, measurement properties and applications. (2003)The economic pressures for biosimilar drug use in cancer medicine (2012)High Cancer Drug Prices in the United States: Reasons and Proposed Solutions (2014)Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions? (2015)Cost-Effectiveness in Health and Medicine (1996)Decision Modelling For Health Economic Evaluation (2006)Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves (2012)Planning for Long-Term Follow-Up: Strategies Learned from Longitudinal Studies (2015)Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling (2016)Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now? (2020)Free for All? Lessons from the RAND Health Insurance Experiment (1995)Estimating the Economic Burden of Racial Health Inequalities in the United States (2011)A community empowerment approach to the HIV response among sex workers: effectiveness, challenges, and considerations for implementation and scale-up (2014)Generic and Disease-Specific Measures in Assessing Health Status and Quality of Life (1989)Deriving a Preference-Based Measure for Cancer Using the EORTC QLQ-C30 (2011)Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). (2012)Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients (2018)Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia (2018)German value sets for the EORTC QLU-C10D, a cancer-specific utility instrument based on the EORTC QLQ-C30 (2019)The Role of Cost-effectiveness Analysis in Health and Medicine (1996)The Role of Cost-effectiveness Analysis in Health and Medicine (1996)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial (2009)Cancer Therapy Costs Influence Treatment: A National Survey Of Oncologists (2010)Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists (2013)Chapter 22 Panel data (1984)Panel data from time series of cross-sections (1985)The Value of a Statistical Life: A Critical Review of Market Estimates Throughout the World (2003)Age Differences in the Value of Statistical Life: Revealed Preference Evidence (2007)The Value of a Statistical Life: Evidence from Panel Data (2011)Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds (2016)
this work references cited by second hop· second hop is a sample of the most-cited connections

References

  • 2014Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold2,303 cited
  • 2008What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?578 cited
  • 2013Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data541 cited
  • 2008Adjusting the Value of a Statistical Life for Age and Cohort Effects363 cited
  • 2006Do Oncologists Believe New Cancer Drugs Offer Good Value?187 cited
  • 2009Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing119 cited
  • 2010Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study112 cited
  • 2014Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma76 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work